tiprankstipranks
Advertisement
Advertisement

SE:HNSA Stock Latest News

RatingsHansa Biopharma: Buy Rating Reiterated as SERB Deal De-Risks Balance Sheet; SEK103 Price Target Maintained on U.S. Opportunity Upside
4d ago
PremiumCompany Announcements
Hansa Biopharma Licenses IDEFIRIX to SERB in €115 Million Europe–MENA Deal
5d ago
PremiumCompany Announcements
Hansa Biopharma CEO to Discuss Scaling Nordic Biotechs at LSX Nordic Congress
5d ago
PremiumCompany Announcements
Hansa Biopharma to Highlight Immunotherapy Platform at H.C. Wainwright BioConnect Conference
11d ago
PremiumCompany Announcements
Hansa Biopharma Calls 2026 AGM With Governance and Incentive Plan on Agenda
26d ago
PremiumCompany AnnouncementsHansa Biopharma Balances Setback and Progress on Earnings
26d ago
Premium
Ratings
Buy Rating Maintained on Hansa Biopharma as Temporary Q1 Weakness Sets Stage for Rebound and Long-Term Growth
29d ago
Premium
Company Announcements
Hansa Biopharma Extends Cash Runway and Advances Imlifidase Toward Key U.S. FDA Decision
1M ago
PremiumCompany Announcements
Hansa Biopharma sets Q1 2026 earnings call and business update
2M ago
Hansa Biopharma Raises USD 30 Million via Convertible Notes to Back U.S. Imlifidase Launch
PremiumCompany Announcements
Hansa Biopharma Raises USD 30 Million via Convertible Notes to Back U.S. Imlifidase Launch
2M ago
Hansa Biopharma to Present Commercial Strategy at Redeye Life Science Event
PremiumCompany Announcements
Hansa Biopharma to Present Commercial Strategy at Redeye Life Science Event
2M ago
Hansa Biopharma to Spotlight Immunomodulatory Platform at DNB Carnegie Healthcare Conference
PremiumCompany Announcements
Hansa Biopharma to Spotlight Immunomodulatory Platform at DNB Carnegie Healthcare Conference
2M ago
Hansa Biopharma leadership to spotlight growth strategy at LSX Investival USA
PremiumCompany AnnouncementsHansa Biopharma leadership to spotlight growth strategy at LSX Investival USA
3M ago
Hansa Biopharma to Spotlight Immunomodulatory Platform at Leerink Global Healthcare Conference
Premium
Company Announcements
Hansa Biopharma to Spotlight Immunomodulatory Platform at Leerink Global Healthcare Conference
3M ago
Imlifidase: Extended FDA Review Seen as Timing-Driven, Not Risk-Driven, Supporting Buy Rating on Strong Unmet-Need and Efficacy Profile
Premium
Ratings
Imlifidase: Extended FDA Review Seen as Timing-Driven, Not Risk-Driven, Supporting Buy Rating on Strong Unmet-Need and Efficacy Profile
3M ago
Hansa Biopharma Secures FDA PDUFA Date for Imlifidase in High-Risk Kidney Transplant Patients
PremiumCompany Announcements
Hansa Biopharma Secures FDA PDUFA Date for Imlifidase in High-Risk Kidney Transplant Patients
3M ago
Hansa Biopharma’s Anti-GBM Phase 3 Trial Termination: What Investors Should Know
PremiumCompany Announcements
Hansa Biopharma’s Anti-GBM Phase 3 Trial Termination: What Investors Should Know
3M ago
HNSA
Hansa Biopharma to Present Corporate Strategy at TD Cowen Health Care Conference
PremiumCompany Announcements
Hansa Biopharma to Present Corporate Strategy at TD Cowen Health Care Conference
3M ago
Imlifidase’s Accelerated Approval Momentum and Long‑Term Graft Outcomes Support a Buy Rating on Hansa Biopharma
PremiumRatings
Imlifidase’s Accelerated Approval Momentum and Long‑Term Graft Outcomes Support a Buy Rating on Hansa Biopharma
3M ago
Hansa Biopharma Wins FDA Review Acceptance for Imlifidase Kidney Transplant Therapy
PremiumCompany AnnouncementsHansa Biopharma Wins FDA Review Acceptance for Imlifidase Kidney Transplant Therapy
3M ago
Hansa Biopharma price target lowered to SEK 103 from SEK 111 at H.C. Wainwright
Premium
The Fly
Hansa Biopharma price target lowered to SEK 103 from SEK 111 at H.C. Wainwright
3M ago
Hansa Biopharma Earnings Call Marks Pivotal 2026 Pivot
Premium
Company Announcements
Hansa Biopharma Earnings Call Marks Pivotal 2026 Pivot
3M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >